QuantaMatrix Inc.
QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early dia… Read more
QuantaMatrix Inc. (317690) - Total Liabilities
Latest total liabilities as of September 2025: ₩14.65 Billion KRW
Based on the latest financial reports, QuantaMatrix Inc. (317690) has total liabilities worth ₩14.65 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
QuantaMatrix Inc. - Total Liabilities Trend (2017–2024)
This chart illustrates how QuantaMatrix Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
QuantaMatrix Inc. Competitors by Total Liabilities
The table below lists competitors of QuantaMatrix Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NAU IB Capital
KQ:293580
|
Korea | ₩66.47 Billion |
|
Urja Global Limited
NSE:URJA
|
India | ₹1.06 Billion |
|
Atturra Ltd
AU:ATA
|
Australia | AU$161.72 Million |
|
SUN KWANG CO.Ltd
KQ:003100
|
Korea | ₩258.43 Billion |
|
I-Tech
ST:ITECH
|
Sweden | Skr19.35 Million |
|
Chi Sheng Chemical
TWO:4111
|
Taiwan | NT$550.20 Million |
|
Qua Granite Hayal Yapi ve Urunleri Sanayi Ticaret AS
IS:QUAGR
|
Turkey | TL10.51 Billion |
|
DK-Lok Corporation
KQ:105740
|
Korea | ₩84.03 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down QuantaMatrix Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how QuantaMatrix Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for QuantaMatrix Inc. (2017–2024)
The table below shows the annual total liabilities of QuantaMatrix Inc. from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩20.30 Billion | +346.42% |
| 2023-12-31 | ₩4.55 Billion | -20.49% |
| 2022-12-31 | ₩5.72 Billion | +6.37% |
| 2021-12-31 | ₩5.38 Billion | +29.42% |
| 2020-12-31 | ₩4.15 Billion | +6.20% |
| 2019-12-31 | ₩3.91 Billion | -94.57% |
| 2018-12-31 | ₩71.96 Billion | +78.06% |
| 2017-12-31 | ₩40.41 Billion | -- |